may be a biomarker for longer survival in patients with surgically resected non-small cell lung cancer

In early-stage lung cancers CLU represents a positive biomarker correlating with better overall survival.[Review]

both cytoplasmic and nuclear immunostaining patterns of clusterin were detected in the tumors of patients with non-small cell lung cancer.

results indicated lower metastatic potential for lung cancer cells with high CLU level

report abundance levels of CLI in serum samples from patients with advanced breast cancer, colorectal cancer (CRC) and lung cancer compared to healthy controls (age and gender matched) using commercially available enzyme-linked immunosorbent assay kits

sCLU plays a positive role in non-small cell lung cancer cell proliferation, which may be mediated by the PI3K/AKT signaling pathway.

biomarker for fewer relapses and longer survival in patients in the early stage adenocarcinomas of the lung

sCLU overexpression decreased cisplatin chemosensitivity of lung cancer.

we identified sCLU as a novel miR-378 target, and we showed that targeting sCLU via miR-378 may help disable the chemoresistance against cisplatin in lung adenocarcinoma cells.

Our study may help to further elucidate the development and progression of non-small cell lung cancer , also it may contribute to the research of therapies targeting sCLU.

Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-kappaB signaling axis in lung cancer cells and denotes a therapeutic opportunity.